Ionis Pharmaceuticals Inc. (NASDAQ:IONS) went down by -3.29% from its latest closing price compared to the recent 1-year high of $48.82. The company’s stock price has collected -1.08% of loss in the last five trading sessions. Barron’s reported on 03/23/21 that Ionis Stock Plunges as Monitoring Board Halts Huntington’s Disease Trial
Is It Worth Investing in Ionis Pharmaceuticals Inc. (NASDAQ :IONS) Right Now?
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) scored a price-to-earnings ratio above its average ratio, recording 679.66 x from its present earnings ratio. Plus, the 36-month beta value for IONS is at 0.54. Opinions of the stock are interesting as 11 analysts out of 23 who provided ratings for Ionis Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 6 rated it as “hold,” and 3 as “sell.”
The average price from analysts is $50.57, which is $10.74 above the current price. IONS currently public float of 141.26M and currently shorts hold a 6.15% ratio of that float. Today, the average trading volume of IONS was 1.10M shares.
IONS’s Market Performance
IONS stocks went down by -1.08% for the week, with a monthly jump of 1.28% and a quarterly performance of -12.07%, while its annual performance rate touched 31.36%. The volatility ratio for the week stands at 2.83% while the volatility levels for the past 30 days are set at 3.41% for Ionis Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 1.61% for IONS stocks with a simple moving average of -2.88% for the last 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with Morgan Stanley repeating the rating for IONS by listing it as a “Equal-Weight.” The predicted price for IONS in the upcoming period, according to Morgan Stanley is $40 based on the research report published on December 21st of the previous year 2022.
Morgan Stanley, on the other hand, stated in their research note that they expect to see IONS reach a price target of $57. The rating they have provided for IONS stocks is “Overweight” according to the report published on September 09th, 2022.
Oppenheimer gave a rating of “Outperform” to IONS, setting the target price at $59 in the report published on July 18th of the previous year.
IONS Trading at -1.12% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.25% of loss for the given period.
Volatility was left at 3.41%, however, over the last 30 days, the volatility rate increased by 2.83%, as shares surge +1.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.70% lower at present.
During the last 5 trading sessions, IONS fell by -1.08%, which changed the moving average for the period of 200-days by +3.00% in comparison to the 20-day moving average, which settled at $38.83. In addition, Ionis Pharmaceuticals Inc. saw 4.37% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at IONS starting from HOUGEN ELIZABETH L, who sale 8,280 shares at the price of $39.70 back on Jan 18. After this action, HOUGEN ELIZABETH L now owns 73,435 shares of Ionis Pharmaceuticals Inc., valued at $328,721 using the latest closing price.
Geary Richard S, the EVP, Chief Development Officer of Ionis Pharmaceuticals Inc., sale 7,873 shares at $39.57 during a trade that took place back on Jan 18, which means that Geary Richard S is holding 70,483 shares at $311,525 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -3.72 for the present operating margin
- +96.25 for the gross margin
The net margin for Ionis Pharmaceuticals Inc. stands at -3.53. Equity return is now at value 1.10, with 0.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 9.75.